Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market

Apr 26, 2012, 07:22 ET from Reportlinker

NEW YORK, April 26, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market

http://www.reportlinker.com/p0845624/Antivirals-Market-to-2017---Increased-Uptake-of-High-Priced-Combination-Drugs-will-Offset-the-Impact-of-Generics-in-the-HIV-Therapeutics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market

Summary GBI Research, the leading business intelligence provider, has released its latest research "Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market", which essentially provides insights into antivirals therapeutics sales forecasts until 2017. The report covers the key geographies of the US, the top five countries in the European region and Japan. Insights into the antiviral research and development pipeline and the potential future blockbusters by 2017 are included. The report provides an in-depth analysis of HIV, hepatitis, herpes and influenza therapeutic indications, and includes market forecasts and treatment usage patterns for these four therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving antiviral therapies is also presented.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The global Antivirals market shows a moderate growth in the pharmaceutical market and is expected to increase further due to increase in the diseased population, increase in awareness level and launch of new drugs with better efficacy. Some major patent expiries are expected during the forecast period, such as for Sustiva, Combivir, Tenofovir, Telbivudine, Tamiflu and Relenza (by 2017). The patent expiries of these blockbuster drugs will trigger generic competition in the antivirals therapeutics market, making it more competitive. The late stage pipeline drugs such as Rilpivirine, Vicriviroc, Elvitegravir, Inavir and Rapiacta are expected to enter the market, which will positively impact the market.

In 2010, the global antivirals market was estimated to be worth $22.1 billion and is expected to reach revenues of approximately $30.1 billion by 2017 at a CAGR of 4.5% between 2010 and 2017. Overall antiviral market is driven by Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for 61% of the market 2010. The Research and Development (R&D) pipeline appears moderately strong with 483 molecules, 33% of which are in Phase II.

Scope

- Data and analysis on HIV, Hepatitis, Herpes and Influenza therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan. - Annualized market data for the antivirals therapeutics market from 2002 to 2010 with forecasts to 2017.Market Data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.- Key drivers and restraints that have had a significant impact on the market.- Competitive landscape of the global antivirals therapeutics market including top companies benchmarking. The key companies studied in this report are Gilead, Merck, GlaxoSmithKline, Roche and Bristol Myers Squibb.- Key M&A activities and licensing agreements that have taken place in the global antivirals market.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.- Align your product portfolio to the markets with high growth potential.- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.- Develop key strategic initiatives by understanding the key focus areas of leading companies.1 Table of Contents1 Table of Contents 41.1 List of Tables 71.2 List of Figures 92 Antivirals Market to 2017 - Introduction 112.1 Introduction 112.2 GBI Research Report Guidance 113 Antivirals Market to 2017 - Market Overview 123.1 Market Forecasts 123.1.1 Revenue 123.1.2 Global Branded vs Generic Market Share 143.1.3 Annual Cost of Therapy 153.1.4 Treatment Usage Patterns 163.2 Drivers and Restraints for the Global Antivirals Therapeutics Market 183.2.1 Market Drivers 183.2.2 Market Restraints 194 Antivirals Market to 2017 - Geographical Landscape 204.1 Revenue Analysis by Geography 204.2 The US 224.2.1 Revenue 224.2.2 Annual Cost of Therapy 234.2.3 Treatment Usage Patterns 244.3 Top Five Countries of Europe 264.3.1 Revenue 264.3.2 Annual Cost of Therapy 274.3.3 Treatment Usage Patterns 284.4 Japan 304.4.1 Revenue 304.4.2 Annual Cost of Therapy 314.4.3 Treatment Usage Patterns 325 Antivirals Market to 2017 - Therapeutic Landscape 345.1 HIV/AIDS Therapeutics Market Forecasts 345.1.1 Introduction 345.1.2 Revenue 365.1.3 Branded vs Generic Market Share 385.1.4 Revenue Analysis by Country 395.1.5 Annual Cost of Therapy 415.1.6 Treatment Usage Patterns 425.2 Drivers and Restraints for the Global HIV/AIDS Therapeutics Market 485.2.1 Market Drivers 485.2.2 Market Restraints 505.3 Hepatitis Therapeutics Market Forecasts 525.3.1 Introduction 525.3.2 Revenue 555.3.3 Branded vs Generic Market Share 575.3.4 Revenue Analysis by Country 585.3.5 Annual Cost of Therapy 605.3.6 Treatment Usage Patterns 615.4 Drivers and Restraints for the Global Hepatitis Therapeutics Market 635.4.1 Market Drivers 635.4.2 Market Restraints 645.5 Herpes Therapeutics Market Forecasts 645.5.1 Introduction 645.5.2 Revenue 675.5.3 Branded vs Generic Market Share 685.5.4 Revenue Analysis by Country 695.5.5 Annual Cost of Therapy 715.5.6 Treatment Usage Pattern 725.6 Drivers and Restraints for the Global Herpes Therapeutics Market 735.6.1 Market Drivers 735.6.2 Market Restraints 745.7 Influenza Therapeutics Market Forecasts 755.7.1 Introduction 755.7.2 Revenue 775.7.3 Branded vs Generic Market Share 785.7.4 Revenue Analysis by Country 795.7.5 Annual Cost of Therapy 805.7.6 Treatment Usage Patterns 815.8 Drivers and Restraints for the Global Influenza Therapeutics Market 835.8.1 Market Drivers 835.8.2 Market Restraints 836 Antivirals Market to 2017 - Pipeline Analysis 846.1 R&D Pipeline by Phase 846.2 R&D Pipeline by Indication 856.3 R&D Pipeline - HIV/AIDS 866.3.1 Overview 866.3.2 Pipeline by Clinical Phase of Development 876.4 Promising Molecules under Development - HIV/AIDS 926.4.1 Quad 926.4.2 Elvitegravir 926.4.3 GSK1349572 936.5 R&D Pipeline - Hepatitis 946.5.1 Overview 946.5.2 R&D Pipeline by Indications 956.6 Promising Molecules under Development - Vaccines for Hepatitis B 1046.6.1 Heplisav 1046.6.2 Spi-VEC 1056.7 Promising Molecules under Development - Therapeutics for Hepatitis B 1056.7.1 Entecavir plus Adefovir Combination Therapy 1056.7.2 Tenofovir plus Emtricitabine Combination Therapy 1066.7.3 Pegylated Interferon Alfa-2a + Adefovir 1066.8 Promising Molecules under Development - Therapeutics for Hepatitis C 1076.8.1 Zalbin (albinterferon alfa-2b, Joulferon) 1076.8.2 RG 7128 1086.9 R&D Pipeline - Herpes 1096.9.1 Overview 1096.9.2 R&D Pipeline by Indication 1106.9.3 Herpes Simplex - Pipeline by Clinical Phase of Development 1106.9.4 Herpes Zoster - Pipeline by Clinical Phase of Development 1126.10 Promising Molecules under Development - Herpes 1136.10.1 BA-021 1136.10.2 NB-001 1136.10.3 ARYS-01 1146.10.4 GSK 1437173A 1156.10.5 V212 1156.11 R&D Pipeline - Influenza 1166.11.1 Overview 1166.11.2 Pipeline by Clinical Phase of Development 1176.12 Promising Molecules under Development - Influenza 1206.12.1 S-021812 1206.12.2 CS-8958 1216.12.3 T-705 1217 Antivirals Market to 2017: Competitive Landscape 1227.1 Profiles of Major Companies 1227.1.1 GlaxoSmithKline (GSK) 1227.1.2 Merck 1237.1.3 F. Hoffmann-La Roche Ltd. 1247.1.4 Gilead Sciences, Inc 1257.1.5 Bristol-Myers Squibb (BMS) 1268 Antivirals Market to 2017 - Strategic Consolidations 1278.1 Mergers and Acquisitions 1278.1.1 Segmentation by Indication 1278.1.2 Segmentation by Geography 1288.1.3 Segmentation by Deal Value 1298.1.4 Major Mergers and Acquisitions Deals 1308.2 Licensing Deals 1328.2.1 Segmentation by Indication 1328.2.2 Segmentation by Geography 1338.2.3 Segmentation by Deal Value 1348.2.4 Major Licensing Deals 1359 Antivirals Market to 2017 - Appendix 1399.1 Market Definitions 1399.2 Abbreviations 1399.3 Research Methodology 1419.3.1 Coverage 1419.3.2 Secondary Research 1419.3.3 Primary Research 1419.4 Research Methodology 1429.4.1 Therapeutic Landscape 1429.4.2 Geographical Landscape 1459.4.3 Pipeline Analysis 1459.4.4 Competitive Landscape 1459.5 Expert Panel Validation 1459.6 Contact Us 1459.7 Disclaimer 1459.8 Sources 146

1.1 List of Tables

Table 1: Antivirals Market, Global, Revenue ($bn), 2002-2010 12Table 2: Antivirals Market, Global, Revenue Forecasts ($bn), 2010-2017 12Table 3: Antivirals Market, Global, Market Share by Indication, (%), 2010 13Table 4: Antivirals Market, Global, Annual Cost of Therapy ($), 2002-2010 15Table 5: Antivirals Market, Global, Annual Cost of Therapy ($), 2010-2017 15Table 6: Antivirals Market, Global, Treatment Usage Patterns (Millions), 2002-2010 16Table 7: Antivirals Market, Global, Treatment Usage Patterns (Millions), 2010-2017 17Table 8: Antivirals Market, Global, Revenue by Country ($m), 2002-2010 20Table 9: Antivirals Market, Global, Revenue Forecasts by Country ($m), 2010-2017 21Table 10: Antivirals Market, The US, Revenue ($m), 2002-2010 22Table 11: Antivirals Market, The US, Revenue Forecasts ($m), 2010-2017 22Table 12: Antivirals Market, The US, Annual Cost of Therapy ($), 2002-2010 23Table 13: Antivirals Market, The US, Annual Cost of Therapy ($), 2010-2017 23Table 14: Antivirals Market, The US, Treatment Usage Patterns (Millions), 2002-2010 24Table 15: Antivirals Market, The US, Treatment Usage Patterns (Millions), 2010-2017 25Table 16: Antivirals Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 26Table 17: Antivirals Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 26Table 18: Antivirals Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2010 27Table 19: Antivirals Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017 27Table 20: Antivirals Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2010 28Table 21: Antivirals Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2010-2017 29Table 22: Antivirals Market, Japan, Revenue ($m), 2002-2010 30Table 23: Antivirals Market, Japan, Revenue Forecasts ($m), 2010-2017 30Table 24: Antivirals Market, Japan, Annual Cost of Therapy ($), 2002-2010 31Table 25: Antivirals Market, Japan, Annual Cost of Therapy ($), 2010-2017 31Table 26: Antivirals Market, Japan, Treatment Usage Patterns (Millions), 2002-2010 32Table 27: Antivirals Market, Japan, Treatment Usage Patterns (Millions), 2010-2017 33Table 28: HIV/AIDS Therapeutics Market, Global, Revenue ($m), 2002–2010 36Table 29: HIV/AIDS Therapeutics Market, Global, Revenue Forecasts ($m), 2010–2017 36Table 30: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenue ($m), 2002–2010 39Table 31: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenue ($m), 2010–2017 40Table 32: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2010 41Table 33: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2010–2017 41Table 34: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns ('000), 2002–2010 43Table 35: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns ('000), 2010–2017 43Table 36: HIV/AIDS Therapeutics Market, Global, Key Drugs Going Off Patent, 2010–2017 51Table 37: Hepatitis Therapeutics Market, Global, Revenue ($m), 2002–2010 55Table 38: Hepatitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010–2017 55Table 39: Hepatitis Therapeutics Market, Global, Revenue by Geography ($m), 2002–2010 58Table 40: Hepatitis Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2010–2017 59Table 41: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2010 60Table 42: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2010–2017 60Table 43: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern ('000s), 2002–2010 61Table 44: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern ('000s), 2010–2017 62Table 45: Herpes Therapeutics Market, Global, Revenue ($bn), 2002–2010 67Table 46: Herpes Therapeutics Market, Global, Revenue Forecasts ($bn), 2010–2017 67Table 47: Herpes Therapeutics Market, Global, Revenue by Geography ($m), 2002–2010 69Table 48: Herpes Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2010–2017 70Table 49: Herpes Market, Global, Annual Cost of Therapy ($), 2002–2010 71Table 50: Herpes Market, Global, Annual Cost of Therapy ($), 2010-2017 71Table 51: Herpes Market, Global, Treatment Usage Patterns (Millions), 2002–2010 72Table 52: Herpes Market, Global, Treatment Usage Patterns (Millions), 2010–2017 72Table 53: Influenza Therapeutics Market, Global, Revenue ($bn), 2002–2010 78Table 54: Influenza Therapeutics Market, Global, Revenue Forecasts ($bn), 2010–2017 78Table 55: Influenza Therapeutics Market, Global Revenue by Country ($m), 2002–2010 79Table 56: Influenza Therapeutics Market, Global Revenue Forecasts by Country ($m), 2010–2017 80Table 57: Influenza Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2010 80Table 58: Influenza Therapeutics Market, Global, Annual Cost of Therapy ($), 2010–2017 81Table 59: Influenza Therapeutics Market, Global, Treatment Usage Patterns (Million), 2002–2010 81Table 60: Influenza Therapeutics Market, Global, Treatment Usage Patterns (Million), 2010–2017 82Table 61: Antivirals Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 84Table 62: Antivirals Therapeutics Market, Global, Pipeline Molecules by Indication (%), 2011 85Table 63: HIV/AIDS Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 86Table 64: HIV/AIDS Therapeutics Market, Global, Discovery Pipeline Molecules, 2011 87Table 65: HIV/AIDS Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 88Table 66: HIV/AIDS Therapeutics Market, Global, Phase I Pipeline Molecules, 2011 89Table 67: HIV/AIDS Therapeutics Market, Global, Phase II Pipeline Molecules, 2011 90Table 68: HIV/AIDS Therapeutics Market, Global, Phase III Pipeline Molecules, 2011 91Table 69: Hepatitis Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 94Table 70: Hepatitis Market, Global, R&D Pipeline by Indication (%), 2011 95Table 71: Hepatitis B Therapeutics Market, Global, Pipeline, 2011 96Table 72: Hepatitis B Vaccines Market, Global, Pipeline, 2011 97Table 73: Hepatitis C Therapeutics Market, Global, Pipeline, 2011 98Table 74: Herpes Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 109Table 75: Herpes Market, Global, R&D Pipeline by Indication (%), 2011 110Table 76: Herpes Simplex Market, Global, Discovery and IND Filed Pipeline Molecules, 2011 110Table 77: Herpes Simplex Market, Global, Pre-Clinical Pipeline Molecules, 2011 111Table 78: Herpes Simplex Market, Global, Phase I Pipeline Molecules, 2011 111Table 79: Herpes Simplex Market, Global, Phase II Pipeline Molecules 2011 111Table 80: Herpes Simplex Market, Global, Phase III and NDA Filed Pipeline Molecules 2011 112Table 81: Herpes Zoster Market, Global, Pre-Clinical and Phase II Pipeline Molecules 2011 112Table 82: Herpes Zoster Market, Global, Phase III Pipeline Molecules 2011 112Table 83: Influenza Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 116Table 84: Influenza Therapeutics Market, Global, Discovery Pipeline Molecules, 2011 117Table 85:Influenza Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 118Table 86:Influenza Therapeutics Market, Global, Phase I Pipeline Molecules, 2011 119Table 87:Influenza Therapeutics Market, Global, Phase II Pipeline Molecules, 2011 119Table 88:Influenza Therapeutics Market, Global, Phase III/NDA filed Pipeline Molecules, 2011 120Table 89:Antivirals Market, Global, M&A Deals by Indication,2004-2011 127Table 90:Antivirals Market, Global, M&A Deals by Geography, 2004-2011 128Table 91:Antivirals Market, Global, M&A Deals by Deal Value, 2004-2011 129Table 92:Antivirals Market, Global, Licensing Deals by Indication, 2004-2011 132Table 93:Antivirals Market, Global, Licensing Deals by Geography, 2004-2011 133Table 94:Antivirals Market, Global, Licensing Deals by Deal Value, 2004-2011 134

1.2 List of Figures

Figure 1: Antivirals Market, Global, Revenue Forecasts ($bn), 2002-2017 12Figure 2: Antivirals Market, Global, Market Share by Indication (%), 2010 13Figure 3: Antivirals Market, Global, Branded vs Generic Market Share (%), 2010 and 2017 14Figure 4: Antivirals Market, Global, Annual Cost of Therapy ($), 2002-2017 15Figure 5: Antivirals Market, Global, Treatment Usage Patterns (Millions), 2002-2017 16Figure 6: Antivirals Market, Global, Market Drivers and Restraints, 2010 18Figure 7: Antivirals Market, Global, Revenue Forecasts by Country ($m), 2002-2017 20Figure 8: Antivirals Market, The US, Revenue Forecasts ($m), 2002-2017 22Figure 9: Antivirals Market, The US, Annual Cost of Therapy ($), 2002-2017 23Figure 10: Antivirals Market, The US, Treatment Usage Patterns (Millions), 2002-2017 24Figure 11: Antivirals Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 26Figure 12: Antivirals Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2017 27Figure 13: Antivirals Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2017 28Figure 14: Antivirals Market, Japan, Revenue Forecasts ($m), 2002-2017 30Figure 15: Antivirals Market, Japan, Annual Cost of Therapy ($), 2002-2017 31Figure 16: Antivirals Market, Japan, Treatment Usage Patterns (Millions), 2002-2017 32Figure 17: HIV/AIDS Therapeutics Market, Global, HIV/AIDS Treatment Flow Algorithm, 2011 35Figure 18: HIV/AIDS Therapeutics Market, Global, Revenue Forecasts ($m), 2002–2017 36Figure 19: HIV/AIDS Therapeutics Market, Global, Branded vs Generic Market Share (%), 2010 and 2017 38Figure 20: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenue ($m), 2002–2017 39Figure 21: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2017 41Figure 22: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns, 2002–2017 42Figure 23: HIV/AIDS Therapeutics Market, Global, Diseased Population, 2002–2017 44Figure 24: HIV/AIDS Therapeutics Market, Global, Treatment Seeking Population, 2002–2017 45Figure 25: HIV/AIDS Therapeutics Market, Global, Diagnosis Population, 2002–2017 46Figure 26: HIV/AIDS Therapeutics Market, Global, Prescription Population, 2002–2017 47Figure 27: HIV/AIDS Therapeutics Market, Global, Market Drivers and Restraints, 2010 48Figure 28: Hepatitis Market, Global, Hepatitis B-Genotypes Based on Geographic Origins 53Figure 29: Hepatitis Market, Hepatitis Treatment Flow Pathway, 2011 54Figure 30: Hepatitis Therapeutics Market, Global, Revenue Forecasts ($m), 2002–2017 55Figure 31: Hepatitis Therapeutics Market, Global, Branded vs Generic Market Share (%), 2010 and 2017 57Figure 32: Hepatitis Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2002–2017 58Figure 33: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2017 60Figure 34: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2002–2017 61Figure 35: Hepatitis Therapeutics Market, Global, Drivers and Restraints, 2011 63Figure 36: Herpes Therapeutics Market, Global, Treatment Algorithm 66Figure 37: Herpes Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017 67Figure 38: Herpes Therapeutics Market, Global, Branded vs Generic Market Share, 2010 and 2017 68Figure 39: Herpes Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2002–2017 69Figure 40: Herpes Market, Global, Annual Cost of Therapy ($), 2002–2017 71Figure 41: Herpes Market, Global, Treatment Usage Patterns (Millions), 2002–2017 72Figure 42: Herpes Therapeutics Market, Global, Drivers and Restraints, 2010 73Figure 43: Influenza Therapeutics Market, Treatment Flow Algorithm for Influenza, 2011 76Figure 44: Influenza Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017 77Figure 45: Influenza Therapeutics Market, Global, Branded vs Generic Market Share (%), 2010 and 2017 78Figure 46: Influenza Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2002–2017 79Figure 47: Influenza Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2017 80Figure 48: Influenza Therapeutics Market, Global, Treatment Usage Patterns (Million), 2002–2017 81Figure 49: Influenza Therapeutics Market, Global, Drivers and Restraints, 2010 83Figure 50: Antivirals Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 84Figure 51: Antivirals Therapeutics Market, Global, Pipeline Molecules by Indication (%), 2011 85Figure 52: HIV/AIDS Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 86Figure 53: Hepatitis Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 94Figure 54: Hepatitis Market, Global, R&D Pipeline by Indication (%), 2011 95Figure 55: Herpes Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 109Figure 56: Herpes Market, Global, R&D Pipeline by Indication (%), 2011 110Figure 57: Influenza Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 116Figure 58: Antivirals Market, GlaxoSmithKline, SWOT Analysis, 2011 122Figure 59: Antivirals Market, Merck, SWOT Analysis, 2011 123Figure 60: Antivirals Market, Roche, SWOT Analysis, 2011 124Figure 61: Antivirals Market, Gilead, SWOT Analysis, 2011 125Figure 62: Antivirals Market, Bristol-Myers Squibb, SWOT Analysis, 2011 126Figure 63: Antivirals Market, Global, M&A Deals by Indication (%), 2004-2011 127Figure 64: Antivirals Market, Global, M&A Deals by Geography (%), 2004-2011 128Figure 65: Antivirals Market, Global, M&A Deals by Deal Value (%), 2004-2011 129Figure 66: Antivirals Market, Global, Licensing Deals by Indication (%), 2004-2011 132Figure 67:Antivirals Market, Global, Licensing Deals by Geography (%), 2004-2011 133Figure 68:Antivirals Market, Global, Licensing Deals by Deal Value (%), 2004-2011 134Figure 69: GBI Research Market Forecasting Model 144

Companies mentioned

GlaxoSmithKline (GSK)

Merck

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc

Bristol-Myers Squibb (BMS)

To order this report:Therapy Industry: Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market

More  

Market Research Report

Check our  

Industry Analysis and Insights

Contact Nicolas: nicolasbombourg@reportlinker.comUS: (805)-652-2626Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com